Reaction
Reflux Gastritis reporting signals
As of the last recalculation, Reflux Gastritis appears in 1,178 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is SUCRALFATE ORAL (PRR 36.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sucralfate Oral | 29 | 36.9 | 37.0 |
| Sucralfate Oral Suspension | 29 | 36.8 | 36.9 |
| Sucralfate | 38 | 28.9 | 29.0 |
| Anastrozole Tablets | 24 | 20.2 | 20.2 |
| Ribociclib | 34 | 19.6 | 19.6 |
| Everolimus Tablets | 15 | 16.0 | 16.0 |
| Lanreotide Acetate | 6 | 13.6 | 13.6 |
| Anastrozole | 26 | 12.8 | 12.8 |
| Diclofenac Sodium 1% | 22 | 11.1 | 11.1 |
| Diclofenac Sodium Topical | 22 | 11.1 | 11.1 |
| Diclofenac Sodium Topical Gel, 1% | 22 | 11.0 | 11.1 |
| Niraparib | 13 | 10.5 | 10.5 |
| Alpelisib | 5 | 10.2 | 10.2 |
| Everolimus | 27 | 9.6 | 9.6 |
| Vortioxetine | 9 | 9.4 | 9.4 |
| Vigabatrin | 6 | 7.3 | 7.3 |
| Sunitinib Malate | 16 | 7.3 | 7.3 |
| Palivizumab | 4 | 4.6 | 4.6 |
| Nirmatrelvir And Ritonavir | 10 | 3.3 | 3.3 |
| Tirzepatide | 19 | 2.1 | 2.1 |